Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 511-522

  Raman, Siva P ^a   Horton, Karen M ^a   Fishman, Elliot K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

computed tomography; magnetic resonance imaging; Pancreatic adenocarcinoma; positron emission tomography; radiology

Indexed keywords

CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; HUMAN; LYMPHADENOPATHY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

CARCINOMA, PANCREATIC DUCTAL; HUMANS; MAGNETIC RESONANCE IMAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84871187269     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318274a461     Document Type: Review

References (27)

1. Vachiranubhap B, Kim YH, Balci NC, et al. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging. 2009;20:3-9.
2. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med. 2006;36: 248-256.
3. Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clinic N Am. 2002;40:1263-1272.
4. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resect-able pancreatic cancer: definitions, management, and role of preopera-tive therapy. Ann Surg Oncol. 2006;13:1035-1046.
5. Pawlik TM, Laheru D, Hruban RH, et al. Evaluating the impact of single day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15:2081-2088.
6. Fishman EK, Ney DR, Heath DG, et al. Volume rendering versus maximum intensity projection in CT angiography: what works best, when, and why. Radiographics. 2006;26:905-922.
7. Prokesch RW, Schima W, Chow LC, et al. Multidetector CT of pancreatic adenocarcinoma: diagnostic advances and therapeutic relevance. Eur Radiol. 2003;13:2147-1254.
8. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-helical CT. AJR Am J Roentgenol. 1997;168:1439-1443.
9. Iafrate F, Ciolona M, Sammartino P, et al. Peritoneal carcinomatosis: imaging with 64-MDCT and 3T MRI with diffusion-weighted imaging. Abdom Imaging. 2011. In press.
10. Arvold ND, Niemierko A, Mamon HJ, et al. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2011;80:1383-1390.
11. Zamboni GA, Kruskal JB, Vollmer CM, et al. Pancreatic adenocarcino-ma: value of multidetector CT angiography in preoperative evaluation. Radiology. 2007;245:770-778.
12. Miller FH, Rini NJ, Keppke AL. MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol. 2006;187:W365-W374.
13. Ly JN, Miller FH. MR imaging of the pancreas: a practical approach. Radiol Clin N Am. 2002;40:1289-1306.
14. Park HS, Lee JM, Choi HK, et al. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholagiopancreatography versus MDCT. J Magn Reson Imaging. 2009; 30:586-595.
15. Fusari M, Maurea S, Imbriaco M, et al. Comparison between multislice CT and MRI imaging in the diagnostic evaluation of patients with pancreatic masses. Radiol Med. 2010;115:453-466.
16. Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic ade-nocarcinoma at dynamic enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology. 2010;257:87-96.
17. Kalra MK, Maher MM, Mueller PR, et al. State of the art imaging of pancreatic neoplasms. Br J Radiol. 2003;76:857-865.
18. Wang Y, Miller FH, Chen ZE, et al. Diffusion-weighted MR imaging of solid and cystic lesions of the pancreas. Radiographics. 2011;31: E47-E65.
19. Balci NC, PErman WH, Saglam S, et al. Diffusion weighted magnetic resonance imaging of the pancreas. Top Magn Reson Imaging. 2009; 20:43-47.
20. Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging. 2011;36:179-184.
21. Nguyen VX, Nguyen CC, Nguyen BD. F18-FDG PET/CT imaging of the pancreas: spectrum of diseases. J Pancreas (Online). 2011;12: 557-566.
22. Buchs NC, Buhler L, Bucher P, et al. Value of contrast-enhanced F18-fluodeoxyglucose positron emission tomography/computed tomography in detection and preoperative assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol. 2011;26:657-662.
23. Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of F18-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957-963.
24. Grassetto G, Rubello D. Role of FDG-PET/CT in diagnosis, staging, and response to treatment, and prognosis of pancreatic cancer. Am J Clin Oncol. 2011;34:111-114.
25. Lee TY, Kim M, Park DH, et al. Utility of F18-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol. 2009;193: 343-348.
26. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluor-odeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923-929.
27. 18F-fluorodeoxyglucose positron emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas. 2000;20: 109-116.